Key facts
- This page summarizes Michael H. Davidson's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Jun 2024, 08:30.
Michael H. Davidson - 20 Jun 2024 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- NAMS
- Reported as of
- 20 Jun 2024
- Net transaction value
- +$86,308
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2024, 08:30:04 UTC
- Prior SEC filing
- 27 Sep 2024
- Next SEC filing
- 08 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Louise Kooij by Power of Attorney from Michael H. Davidson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael H. Davidson filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 24 Jun 2024.
Change
- Previous filing in this sequence was filed on 27 Sep 2024.
- Current net transaction value: +$86,308.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAMS
transaction
Ordinary Shares
Purchase
- Transaction value
- $86,308
- Shares
- +5,000
- Change %
- +2.5%
- Price
- $17.26
- Shares after
- 204,784
- Date
- 20 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
NAMS
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 608,779
- Date
- 20 Jun 2024
- Ownership
- See footnote
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.115 to $17.60, inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, specific trade amounts and pricing within the range set forth in this footnote at which the transaction was effected.
Footnote F2
The 608,779 Ordinary Shares are held of record by Stichting Administratiekantoor EPNAP ("STAK EPNAP") and are subject to forfeiture underlying depositary receipts issued by STAK EPNAP. STAK EPNAP has sole voting and investment power over the 608,779 Ordinary Shares underlying the depositary receipts and are presented here because the depositary receipts can be cancelled by the board of directors of STAK EPNAP at any time as a consequence of which the Reporting Person will become the beneficial owner of the securities underlying the depositary receipts.